Twelve years after founding now globally recognized Moderna, Kenneth Chien is dipping his toes back into the piping hot waters of mRNA startups.
For now, eTheRNA’s platform is teased at a macro-level, with the company saying it hopes to build out “an integrated set of proprietary capabilities for an end-to-end solution” to all facets of mRNA drug development. The company did, however, zero in on making customized lipoid nanoparticle (cLNP) formulations, in large part because that could become a potential-near term revenue stream via collaborations with “multiple future partners.” More details about the technology weren’t available at the time of publishing, with the company’s website still under construction.
But nonetheless, the game plan seems to resonate with Chien, who in a statement said the company’s strategy is “consistent with my vision of the future in which cLNPs of increasingly sophisticated design will lead to novel applications in a range of currently untreatable diseases.”
“We are excited to lead this new funding round for eTheRNA and help propel the company to contribute its breakthrough technologies to the development of mRNA-based therapeutics, an area that is full of unimaginable opportunities as the coronavirus (COVID-19) vaccine has shown us,” Dekkers said in the press release. Since launching in 2017, Novalis has invested in a variety of biotechs and adjacent companies, including Ginkgo Bioworks and CNS disorder-focused biopharma Cerevel.